

**Table S1.** Correlation of C<sub>T</sub> values and concentration of stool used in preliminary experiments performed with the Seegene Allplex™ SARS-CoV-2/FluA/FluB/RSV (SC2FABR) assay, spiking samples with serial 10-fold dilutions of SARS-CoV-2 viral inactivated lysates. Quantitative evaluations of SARS-CoV-2 viral load (TCID<sub>50</sub>/mL) have been also reported. Abbreviations: TCID, median tissue culture infectious dose; ExoIC, exogenous rRT-PCR control; EndoIC, endogenous rRT-PCR control; nd: not detected.

		Allplex™SARS-CoV-2/FluA/FluB/RSV Assay										
Dilution	Viral titre (TCID <sub>50</sub> /mL)	Stool conc. (mg/mL)	S	C <sub>T</sub>	RdRP	C <sub>T</sub>	N	C <sub>T</sub>	EndoIC	C <sub>T</sub>	ExoIC	C <sub>T</sub>
10 <sup>-1</sup>	2x10 <sup>5</sup>	50	+	21.90	+	21.88	+	27.12	+	28.28	+	30.64
10 <sup>-2</sup>	2x10 <sup>4</sup>		+	27.14	+	28.42	+	35.13	+	31.92	+	34.19
10 <sup>-3</sup>	2x10 <sup>3</sup>		+	29.66	+	30.11	+	36.18	+	36.24	+	32.06
10 <sup>-4</sup>	2x10 <sup>2</sup>		+	34.50	+	37.37	-	N/A	+	38.74	+	34.41
10 <sup>-5</sup>	2x10 <sup>1</sup>		-	N/A	-	N/A	-	N/A	+	38.38	+	34.99
10 <sup>-6</sup>	2		-	N/A	-	N/A	-	N/A	+	33.36	+	36.46
10 <sup>-1</sup>	2x10 <sup>5</sup>	20	+	19.05	+	19.53	+	22.06	+	30.25	+	28.91
10 <sup>-2</sup>	2x10 <sup>4</sup>		+	22.08	+	22.71	+	25.94	+	33.77	+	28.79
10 <sup>-3</sup>	2x10 <sup>3</sup>		+	25.91	+	28.01	+	32.47	+	36.79	+	30.29
10 <sup>-4</sup>	2x10 <sup>2</sup>		+	29.03	+	29.66	+	33.10	+	37.31	+	29.07
10 <sup>-5</sup>	2x10 <sup>1</sup>		+	33.14	+	34.14	+	35.03	-	nd	+	30.61
10 <sup>-6</sup>	2		-	N/A	-	N/A	-	N/A	+	37.40	+	31.07

**Table S2.** Overview of C<sub>T</sub> values of control samples from rRT-PCR experiments performed with the Seegene Allplex™ SARS-CoV-2 (SC2) and SARS-CoV-2/FluA/FluB/RSV (SC2FABR) assays, using serial 10-fold spiked dilutions of SARS-CoV-2 viral inactivated lysates in stool samples and controls (ASL). Quantitative evaluations of SARS-CoV-2 viral load have been also reported. Abbreviations: cp, copies; CV, coefficient of variation; SD, standard deviation; TCID, median tissue culture infectious dose; ExoIC, exogenous rRT-PCR control; EndoIC, endogenous rRT-PCR control.

Dilution	Viral titre (TCID <sub>50</sub> /mL)	RNA cp/μL	RNA cp/mg	Allplex™ SARS-CoV-2				Allplex™ SARS-CoV-2/FluA/FluB/RSV Assays							
				C <sub>T</sub> <sup>ExoIC</sup> (SD)	Percent positivity (n/N)	CV (%)	C <sub>T</sub> <sup>ASL</sup> (SD)	C <sub>T</sub> <sup>EndoIC</sup> (SD)	Percent positivity (n/N)	CV (%)	C <sub>T</sub> <sup>ASL</sup> (SD)	C <sub>T</sub> <sup>ExoIC</sup> (SD)	Percent positivity (n/N)	CV (%)	C <sub>T</sub> <sup>ASL</sup> (SD)
10 <sup>-1</sup>	2x10 <sup>5</sup>	1.03x10 <sup>7</sup>	5.15E+08	23.53 (1.45)	100 (30/30)	6.16	23.34 (1.96)	27.21 (0.98)	100 (30/30)	3.60	27.59 (0.70)	23.28 (0.82)	100 (30/30)	3.52	22.13 (0.95)
10 <sup>-2</sup>	2x10 <sup>4</sup>	1.06x10 <sup>6</sup>	5.30x10 <sup>7</sup>	23.47 (1.58)	100 (30/30)	6.73	23.23 (2.01)	30.04 (0.99)	100 (30/30)	3.30	30.54 (0.64)	23.30 (0.97)	100 (30/30)	4.16	23.20 (0.76)
10 <sup>-3</sup>	2x10 <sup>3</sup>	9.71x10 <sup>4</sup>	4.86x10 <sup>6</sup>	23.68 (1.51)	100 (30/30)	6.38	23.89 (2.00)	32.98 (1.13)	100 (30/30)	3.43	32.96 (1.25)	23.42 (1.02)	100 (30/30)	4.36	23.75 (1.31)
10 <sup>-4</sup>	2x10 <sup>2</sup>	9.97x10 <sup>3</sup>	4.99x10 <sup>5</sup>	23.84 (1.31)	100 (30/30)	5.49	24.17 (1.76)	34.57 (1.43)	100 (30/30)	4.14	34.23 (1.97)	23.21 (0.91)	100 (30/30)	3.92	23.87 (1.32)
10 <sup>-5</sup>	2x10 <sup>1</sup>	9.27x10 <sup>2</sup>	4.64x10 <sup>4</sup>	23.98 (1.49)	100 (30/30)	6.21	24.17 (1.82)	34.44 (1.52)	83.33 (25/30)	4.41	35.69 (3.33)	23.12 (0.74)	100 (30/30)	3.20	23.62 (0.90)
10 <sup>-6</sup>	2	1.33x10 <sup>2</sup>	6.65x10 <sup>3</sup>	24.01 (1.56)	100 (30/30)	6.50	24.26 (2.08)	34.71 (1.63)	86.66 (26/30)	4.70	34.19 (-*)	23.31 (0.80)	100 (30/30)	3.43	23.47 (0.75)